Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SOF-XX
- Development stage
- Preclinical
- Lead developer
- Pharmorage
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Topical, Subcutaneous
01
Overview
SOF-XX is a preclinical-stage ultra-short oligonucleotide (USO) developed by Pharmorage, specifically engineered to target and antagonize Toll-like receptor 7 (TLR7). USOs represent a novel therapeutic modality characterized by their extremely short sequence length (typically 2 to 5 nucleotides), which distinguishes them from traditional antisense oligonucleotides or aptamers. By inhibiting TLR7, SOF-XX prevents the activation of downstream signaling pathways that lead to the overproduction of type I interferons and other pro-inflammatory cytokines. This mechanism is particularly relevant for the treatment of systemic lupus erythematosus (SLE), psoriasis, and various inflammatory skin diseases, where TLR7 signaling is a key driver of chronic inflammation and autoimmunity. The USO platform is designed to offer improved stability and delivery profiles compared to longer oligonucleotide sequences.
- Other names
- TLR7-targeting ultra-short oligonucleotideTLR-7-targeting ultra-short oligonucleotideTLR 7-targeting ultra-short oligonucleotide
02
Targets
TLR8 (Toll-like receptor 8)TLR7 (Toll-like receptor 7)
Beyond the preview
Go deeper on SOF-XX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SOF-XX.